Founded in Irvine, CA, Entelexo Biotherapeutics is dedicated to creating a new class of drugs to address incurable autoimmune diseases. The company's core mission is to develop innovative treatments for immune-mediated conditions like psoriasis using their proprietary engineered exosome technology. Entelexo's vision is to revolutionize the treatment landscape for autoimmune diseases by leveraging the natural cell-to-cell communication system of exosomes to deliver therapeutic messages.
Notable affiliated individuals and investors have yet to be publicly disclosed. Entelexo has achieved significant milestones, including the development of a proprietary engineering platform that allows for rapid prototyping of exosome-based therapeutics. Their initial pipeline of products has been de-risked using human cell assays, demonstrating potential efficacy and safety. Entelexo's impact lies in its innovative approach to treating autoimmune diseases, offering hope for conditions that currently lack effective treatments.
